文献速递基础与转化研究临床试验与 GCP

新诊断胶质母细胞瘤的新辅助三联免疫检查点阻断治疗

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
PubMed 文献 · Nat Med · 2025-02-27

本文报告一例新诊断IDH野生型、MGMT启动子未甲基化胶质母细胞瘤患者,接受单剂新辅助三联免疫检查点阻断(抗PD-1联合抗CTLA-4联合抗LAG-3)后12天行最大安全范围切除。切除肿瘤中抗PD-1药物与肿瘤浸润淋巴细胞结合,TIL浸润和激活较基线活检显著增加,17个月后无明确复发征象。计划开展新诊断胶质母细胞瘤一线新辅助联合检查点抑制剂临床试验(GIANT;试验注册号NCT06816927)。

要点

  • 新辅助三联免疫检查点阻断在胶质母细胞瘤中可诱导TIL浸润和激活。
  • 切除标本中抗PD-1药物与TIL结合,TIL浸润较基线活检明显增加。
  • 患者17个月后无明确复发征象,计划开展一线新辅助联合治疗临床试验。

核心结论

  • 在新诊断胶质母细胞瘤中,一线最大安全范围切除前使用检查点抑制剂能够激活免疫,并可能诱导反应。

研究设计与样本

  • 本文报告一例新诊断IDH野生型、MGMT启动子未甲基化胶质母细胞瘤病例,接受单剂新辅助三联免疫检查点阻断后12天行最大安全范围切除。

主要发现

  • 切除的胶质母细胞瘤中抗PD-1药物与TIL结合,TIL浸润和激活较基线活检显著增加。
  • 治疗后17个月,无明确复发征象。

临床怎么用

  • 作者认为,若在一线最大安全范围切除前使用,检查点抑制剂能够在胶质母细胞瘤中激活免疫并可能诱导反应。
  • 计划开展新诊断胶质母细胞瘤一线新辅助联合检查点抑制剂治疗临床试验(GIANT;试验注册号NCT06816927)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many tumor types, particularly when used neoadjuvantly or as a first-line treatment, including in melanoma brain metastases, they have shown limited efficacy in patients with resected or recurrent GBM. The lack of efficacy has been attributed to the scarcity of tumor-infiltrating lymphocytes (TILs), an immunosuppressive tumor microenvironment and low tumor mutation burden typical of GBM tumors, plus exclusion of large molecules from the brain parenchyma. We hypothesized that upfront neoadjuvant combination immunotherapy, administered with disease in situ, could induce a stronger immune response than treatment given after resection or after recurrence. Here, we present a case of newly diagnosed IDH-wild-type, MGMT promoter unmethylated GBM, treated with a single dose of neoadjuvant triplet immunotherapy (anti-programmed cell death protein 1 plus anti-cytotoxic T-lymphocyte protein 4 plus anti-lymphocyte-activation gene 3) followed by maximal safe resection 12 days later. The anti-programmed cell death protein 1 drug was bound to TILs in the resected GBM and there was marked TIL infiltration and activation compared with the baseline biopsy. After 17 months, there is no definitive sign of recurrence. If used first line, before safe maximal resection, checkpoint inhibitors are capable of immune activation in GBM and may induce a response. A clinical trial of first-line neoadjuvant combination checkpoint inhibitor therapy in newly diagnosed GBM is planned (GIANT; trial registration no. NCT06816927 ).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Long GV, Shklovskaya E, Satgunaseelan L, et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med. 2025. PMID: 40016450. doi:10.1038/s41591-025-03512-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。